CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Revenues:
Product sales	$ 1,500,625	$ 2,443,388	$ 2,260,994
License fee and other revenues	329,956	284,290	386,941
Research and development	325,415	363,572	585,312
Total revenues	2,155,996	3,091,250	3,233,247
Costs and Expenses:
Costs of goods sold	613,591	482,657	1,159,173
Research and development	99,282,874	51,776,395	53,492,471
Sales and marketing	6,822,174	873,154	1,027,139
General and administrative	36,484,641	29,108,777	6,562,555
Total costs and expenses	143,203,280	82,240,983	62,241,338
Operating loss	141,047,284	(79,149,733)	(59,008,091)
Changes in fair market value of warrant liabilities	(108,635,809)	(61,073,808)	0
Warrant related expenses	0	(7,649,395)	0
Interest expense	(23,254,787)	(5,479,821)	(5,479,821)
Interest and other income	5,492,632	430,595	337,901
Other financing expenses	(13,005,329)	(346,568)	0
Insurance reimbursement	6,637,992	0	0
Foreign currency transaction gain (loss), net	81,423	23,311	(39,538)
Loss before income tax	(273,731,162)	(153,245,419)	(64,189,549)
Income tax (expense) benefit	(155,808)	(20,867)	5,053,833
Net loss	(273,886,970)	(153,266,286)	(59,135,716)
Net loss attributable to noncontrolling interest	(50,083)	(60,341)	(98,766)
Net loss attributable to Immunomedics, Inc. stockholders	$ (273,836,887)	$ (153,205,945)	$ (59,036,950)
Loss per common share attributable to Immunomedics, Inc. stockholders (basic and diluted) (in USD per share)	$ (1.78)	$ (1.47)	$ (0.62)
Weighted average shares used to calculate loss per common share (basic and diluted) (in shares)	153,474,943	104,535,577	94,770,172
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments	$ (105,285)	$ (62,085)	$ 1,192
Unrealized gain (loss) on securities available for sale	55,197	(108,399)	27,674
Other comprehensive income (loss), net of tax:	(50,088)	(170,484)	28,866
Comprehensive loss	(273,937,058)	(153,436,770)	(59,106,850)
Comprehensive loss attributable to noncontrolling interest	(50,083)	(60,341)	(98,766)
Comprehensive loss attributable to Immunomedics, Inc. stockholders	$ (273,886,975)	$ (153,376,429)	$ (59,008,084)